Cargando…
Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1/2 clinical trial
BACKGROUND: There are no clinical trials involving patients with diffuse large B-cell lymphoma (DLBCL) in sub-Saharan Africa since antiretroviral therapy (ART) for HIV became widely available in this region. We aimed to establish the safety and efficacy of rituximab plus cyclophosphamide, doxorubici...
Autores principales: | Kimani, Stephen, Painschab, Matthew S, Kaimila, Bongani, Kasonkanji, Edwards, Zuze, Takondwa, Tomoka, Tamiwe, Mulenga, Maurice, Nyasosela, Richard, Chikasema, Maria, Mtangwanika, Asekanadziwa, Chawinga, Mena, Mhango, Wilberforce, Nicholas, Simon, Chimzimu, Fred, Kampani, Coxcilly, Krysiak, Robert, Lilly, Amy, Randall, Cara, Seguin, Ryan, Westmoreland, Katherine D, Montgomery, Nathan D, Fedoriw, Yuri, Gopal, Satish |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338824/ https://www.ncbi.nlm.nih.gov/pubmed/34022150 http://dx.doi.org/10.1016/S2214-109X(21)00181-9 |
Ejemplares similares
-
Modified EPOCH for high‐risk non‐Hodgkin lymphoma in sub‐Saharan Africa
por: Zuze, Takondwa, et al.
Publicado: (2019) -
Plasmablastic lymphoma in Malawi
por: Zuze, Takondwa, et al.
Publicado: (2018) -
Comparison of baseline lymphoma and HIV characteristics in Malawi before and after implementation of universal antiretroviral therapy
por: Gondwe, Yolanda, et al.
Publicado: (2022) -
High pretreatment plasma Epstein‐Barr virus (EBV) DNA level is a poor prognostic marker in HIV‐associated, EBV‐negative diffuse large B‐cell lymphoma in Malawi
por: Montgomery, Nathan D., et al.
Publicado: (2019) -
Comparison of best supportive care, CHOP, or R-CHOP for treatment of diffuse large B-cell lymphoma in Malawi: a cost-effectiveness analysis
por: Painschab, Matthew S, et al.
Publicado: (2021)